KA
RXRX icon

Kinnevik AB’s Recursion Pharmaceuticals RXRX Stock Holding History

Kinnevik AB’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$65.6M Hold
13,434,171
– – 100% 1
2025
Q2 		$68M Hold
13,434,171
– – 100% 1
2025
Q1 		$71.1M Buy
13,434,171
+1,528,503
+13% +$11.1M 100% 1
2024
Q4 		$80.5M Hold
11,905,668
– – 100% 1
2024
Q3 		$78.5M Hold
11,905,668
– – 100% 1
2024
Q2 		$89.3M Buy
11,905,668
+1,500,000
+14% +$13.1M 100% 1
2024
Q1 		$104M Hold
10,405,668
– – 100% 1
2023
Q4 		$103M Hold
10,405,668
– – 100% 1
2023
Q3 		$79.6M Hold
10,405,668
– – 100% 1
2023
Q2 		$77.7M Buy
10,405,668
+2,752,607
+36% +$19.3M 100% 1
2023
Q1 		$51M Hold
7,653,061
– – 68.47% 1
2022
Q4 		$59M Buy
+7,653,061
New +$75M 33.28% 2

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Kinnevik AB's RXRX Position: Q3 2025 in Review

Kinnevik AB held its Recursion Pharmaceuticals (RXRX) position steady in Q3 2025 at 13,434,171 shares worth $65.6M. The position accounts for 100% of the portfolio, ranked #1.

Kinnevik AB first reported a position in RXRX in Q4 2022 and has held it in 12 quarters since. The position peaked at $104M in Q1 2024. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

  • Kinnevik AB held 13,434,171 shares of Recursion Pharmaceuticals worth $65.6M as of Q3 2025.
  • Kinnevik AB left its Recursion Pharmaceuticals share count unchanged in Q3 2025.
  • Recursion Pharmaceuticals made up 100% of Kinnevik AB's portfolio in Q3 2025, its #1 holding.
  • Kinnevik AB first reported a position in Recursion Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
  • Kinnevik AB's Recursion Pharmaceuticals position peaked at $104M in Q1 2024.
  • 322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on Kinnevik AB's 13F filing for Q3 2025, filed 4 Nov 2025.